# Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma

> **NCT02018367** · PHASE2 · UNKNOWN · sponsor: **Anandasabapathy, Sharmila, M.D.** · enrollment: 100 (estimated)

## Conditions studied

- Barrett's Esophagus

## Interventions

- **DRUG:** Proflavine, high resolution imaging

## Key facts

- **NCT ID:** NCT02018367
- **Lead sponsor:** Anandasabapathy, Sharmila, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02018367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02018367, "Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02018367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*